



Department of Immunology

Extension to Scope of Accreditation

Severn Pathology will comply with the requirements of all relevant regulatory bodies and is committed to the use of examination procedures that will ensure the acceptable quality of all tests performed and are fit for their intended use.

The accredited scope of activity for the department is given in the UKAS schedule. From time to time, amendments to this scope may be required, examples include addition of new tests or changes to test methodology. In such cases, the department will apply for Extension to Scope from UKAS. The following tests are currently in this process.

Activity/Test	Sample Type/s	Comments
<b>Anti-MPO/PR3</b>	Serum	ETS platform change from Dynex DS2 QUANTA Lite ELISA to ImmunoCAP 250 ELiA
<b>Anti-GBM</b>	Serum	ETS platform change from Dynex DS2 QUANTA Lite ELISA to ImmunoCAP 250 ELiA
<b>Anti-β2-Glycoprotein 1</b>	Serum	ETS new assay by ImmunoCAP 250 ELiA
<b>Anti-Cardiolipin IgG and IgM</b>	Serum	ETS new assay by ImmunoCAP 250 ELiA
<b>Neutrophil Function: Oxidative Burst</b>	Heparinised plasma	ETS reagent change from Phagoburst kit to DHR123 kit, both on FACSLytic Flow Cytometer.
<b>Alkaline Phosphatase Isoenzymes</b>	Serum	New assay by Sebia Hydrasys 2 Scan Electrophoresis
<b>Oligoclonal Bands</b>	Serum/CSF	New assay by Sebia Hydrasys 2 Scan Electrophoresis
<b>Avian Precipitins</b>	Serum	New assay by ImmunoCAP 250 Allergy